It's not enough to believe a drug trial will be positive. To generate true alpha, an investor must also have a well-researched, specific explanation for what misconceptions or concerns are causing other market participants to misprice the asset.
Abivax's drug was dismissed by many investors because its mechanism of action was unclear, a common red flag. However, the available clinical data was strong enough to suggest efficacy, meaning the "how" it worked was less important than the evidence "that" it worked for generating alpha.
Investors often compare new drugs to the most effective treatments on efficacy alone. In practice, dermatologists will almost always choose a safer drug with lower efficacy first, creating a huge market for treatments that aren't "best-in-class" but have a superior safety profile.
A common mistake in biotech investing is relying too heavily on a company's own data and presentations. To gain a true edge, investors should spend more time diligencing competitor drugs and the broader market landscape, as companies rarely provide an unbiased view of their competition.
Nektar's initial poor trial results were heavily impacted by one patient missing their week 12 appointment, which coincided with a rare, outlier placebo response. This unlucky convergence suppressed the reported drug efficacy, creating a massive misperception of the drug's potential.
After a successful trial readout, it's tempting to sell. However, holding these "graduated" stocks can be smart portfolio construction. They provide stability and moderate upside to balance the binary, high-risk/reward nature of pre-catalyst investments, especially when still inefficiently priced.
While hiring a Chief Commercial Officer (CCO) signals a company might "go it alone," it's a savvy move for a buyout candidate. The small cost creates credible leverage, showing suitors the company has a viable alternative to being acquired, potentially increasing the final buyout price significantly.
By using the public number of patients enrolling in Abivax's maintenance trial (which only responders could join), an investor could mathematically model the pooled response rate and prove the trial would succeed before the official data release, representing profound public-domain alpha.
The market soured on Nektar's alopecia data because of low overall response rates. This misses that the drug is slow-acting and nearly half the patients dropped out before it could take effect. The real efficacy is likely much higher among patients who complete the full treatment course.